alpha-甲基芬太尼 | 79704-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: alpha-甲基芬太尼
• 中文别名: A-METHYLFENTANYL(黑市上出现过,不能做的)
• 英文名称: α-methylfentanyl
• 英文别名: alpha-methylfentanyl；N-phenyl-N-[1-(1-phenylpropan-2-yl)piperidin-4-yl]propanamide
• CAS: 79704-88-4
• 化学式: C₂₃H₃₀N₂O
• 分子量: 350.504
• InChiKey: NGTVDHYUFBKWID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PREPARATION AND UTILITY OF OPIOID ANALGESICS
  申请人：GANT Thomas G.

  公开号：US20080045558A1

  公开（公告）日：2008-02-21

  The present disclosure is directed to modulators of opiate- and/or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and/or glaucoma and any other condition in which it is beneficial to modulate an opiate- and/or NMDA receptor.

  本公开涉及阿片和/或NMDA受体的调节剂及其药用盐和前药，其化学合成，以及利用这些化合物治疗和/或管理疼痛、焦虑、神经退行性疾病、药物依赖、咳嗽、肌肉紧张、和/或青光眼以及任何其他有益于调节阿片和/或NMDA受体的情况。
• SUBSTITUTED 4-AMINO-PIPERIDINES
  申请人：Gant Thomas G.

  公开号：US20100016365A1

  公开（公告）日：2010-01-21

  The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及新的取代4-氨基哌啶类阿片受体调节剂，其药物组成物以及使用方法。
• SUBSTITUTED CYCLOHEXANONES
  申请人：Gant Thomas G.

  公开号：US20080268071A1

  公开（公告）日：2008-10-30

  Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文揭示了基于取代环己酮的Formula I NMDA受体调节剂，其制备方法，相应的药物组合物以及使用方法。
• [EN] FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING<br/>[FR] HAPTÈNES DE FENTANYL, CONJUGUÉS D'HAPTÈNE DE FENTANYL, ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV MINNESOTA

  公开号：WO2021183913A1

  公开（公告）日：2021-09-16

  This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

  这份披露描述了芬太尼半抗原、芬太尼半抗原载体共轭物，制备芬太尼半抗原载体共轭物的方法，以及使用芬太尼半抗原载体共轭物的方法，例如作为一种预防性疫苗来对抗暴露于芬太尼、芬太尼衍生物和芬太尼类似物所产生的毒性。在某些实施方式中，芬太尼半抗原载体共轭物或包含芬太尼半抗原载体共轭物的组合物可用作抗阿片类药物的疫苗。
• PREPARATION AND UTILITY OF SUBSTITUTED CARBOXYLIC ACID COMPOUNDS
  申请人：Gant Thomas G.

  公开号：US20070276042A1

  公开（公告）日：2007-11-29

  The present disclosure is directed to modulators of cyclooxygenase (COX) enzymes and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of non-specific pain, tension-type pain, headache, migraine, lower back pain, sciatica, dental pain, muscular pain, pain associated with acute soft tissue injuries, bursitis, tendonitis, lumbago, periarthritis, tennis elbow, sprains, strains, muscular problems associated with sports injuries, muscular problems associated with accidents, period pain, primary dysmenorrhoea, acute sore throat pain, osteoarthritis, rheumatoid arthritis, cancer, any disorder requiring analgesic response, any disorder requiring anti-inflammatory response, any disorder requiring antipyretic response, any conditions mediated by cyclooxygenase, cystic fibrosis, dementia, Alzheimer's disease, and/or conditions mediated by levels of β-amyloid are described.

  本公开涉及环氧合酶（COX）酶的调节剂及其药用盐和前药，其化学合成，以及这些化合物的医学用途，用于治疗和/或管理非特异性疼痛、紧张性疼痛、头痛、偏头痛、腰痛、坐骨神经痛、牙痛、肌肉疼痛、急性软组织损伤引起的疼痛、滑囊炎、肌腱炎、腰痛、周围关节炎、网球肘、扭伤、拉伤、与运动损伤相关的肌肉问题、与事故相关的肌肉问题、经期疼痛、原发性痛经、急性喉咙疼痛、骨关节炎、类风湿性关节炎、癌症、需要镇痛反应的任何疾病、需要抗炎反应的任何疾病、需要退热反应的任何疾病、任何通过环氧合酶介导的病症、囊性纤维化、痴呆、阿尔茨海默病和/或通过β-淀粉样蛋白水平介导的病症。

表征谱图